BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea
Shares of Regeneron fell 1.2% after hours. The Justice Department’s allegations stem from the way Regeneron subsidizes ...
Hosted on MSN1mon
Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise
As the company faces increasing competition for its flagship product Eylea, it continues to leverage its strong research and development capabilities to expand its pipeline and explore new growth ...